GlassScriptPhysician profile
Susan Williams
NPI 1477118313
$5,073.02
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,573 · 2022: $1,611 · 2023: $1,442 · 2024: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $785.67 | 2021-2024 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $683.28 | 2021-2023 | Provenge |
| Sumitomo Pharma America, INC. | $515.59 | 2023-2024 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $508.88 | 2021-2024 | |
| Blue Earth Diagnostics | $371.54 | 2021-2023 | |
| Urovant Sciences INC | $364.62 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $297.09 | 2021-2024 | Xiaflex, Aveed |
| Amgen INC. | $214.73 | 2021-2023 | Prolia |
| Janssen Biotech, INC. | $128.97 | 2022-2024 | Erleada, Akeega |
| Urogen Pharma, INC. | $124.69 | 2022-2024 | Jelmyto |
| Progenics Pharmaceuticals, INC. | $113.27 | 2021-2023 | Pylarify |
| Abbvie INC. | $87.77 | 2021-2022 | |
| Allergan, INC. | $84.93 | 2021 | |
| Merck Sharp & Dohme LLC | $71.52 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Antares Pharma, INC. | $68.38 | 2021-2023 | Xyosted, Tlando, Nocdurna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $60.24 | 2021 | |
| Clarus Therapeutics INC. | $59.26 | 2021 | |
| Ethicon US, LLC | $59.17 | 2022-2024 | Endopath Xcel, Stratafix, Echelon Flex |
| Pfizer INC. | $58.08 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $52.64 | 2023 | Yonsa |
| Tolmar Pharmaceuticals, INC. | $41.00 | 2021-2022 | |
| Ambu INC. | $38.79 | 2023 | |
| Atricure, INC. | $34.21 | 2023 | |
| Accord Healthcare, INC. | $33.34 | 2023 | |
| Axonics, INC. | $28.88 | 2022-2024 | Axonics |
| Myovant Sciences INC. | $27.08 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $25.34 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $24.73 | 2021-2022 | |
| Tolmar, INC. | $24.06 | 2023 | |
| Endo USA, INC. | $21.48 | 2024 | Aveed, Xiaflex |
| Novartis Pharmaceuticals Corporation | $18.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.59 | 2021 | |
| Photocure INC | $14.90 | 2022 | |
| Metuchen Pharmaceuticals | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.